AMLX (Amylyx Pharmaceuticals) Accumulated Depreciation: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMLX Amylyx Pharmaceuticals Inc AMLX
33 GF Score
Price $38.15
! 3 Warning Signs
View Full Analysis

What is Amylyx Pharmaceuticals Accumulated Depreciation?

Amylyx Pharmaceuticals AMLX -1.32% 33 Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus rates AMLX with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Amylyx Pharmaceuticals's quarterly accumulated depreciation declined from Dec. 2025 ($-1.55 Mil) to Mar. 2026 ($0.00 Mil) but then stayed the same from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Amylyx Pharmaceuticals's annual accumulated depreciation declined from Dec. 2023 ($-1.63 Mil) to Dec. 2024 ($-1.36 Mil) but then increased from Dec. 2024 ($-1.36 Mil) to Dec. 2025 ($-1.55 Mil).

Amylyx Pharmaceuticals Accumulated Depreciation Related Terms

Amylyx Pharmaceuticals Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Amylyx Pharmaceuticals's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amylyx Pharmaceuticals Accumulated Depreciation Chart

Amylyx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial -0.05 -0.54 -1.63 -1.36 -1.55

Amylyx Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.55 0.00 0.00
AMLX
33GF Score
Amylyx Pharmaceuticals Inc AMLX
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amylyx Pharmaceuticals Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $0.00 Mil mean?
Amylyx Pharmaceuticals (AMLX) has a Accumulated Depreciation of $0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Amylyx Pharmaceuticals and its competitors.
Is Amylyx Pharmaceuticals' Accumulated Depreciation too high?
Amylyx Pharmaceuticals' current Accumulated Depreciation is $0.00 Mil. Overall, Amylyx Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' Accumulated Depreciation compare to ANIP and PBH?
Amylyx Pharmaceuticals' Accumulated Depreciation of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Amylyx Pharmaceuticals and its competitors. Amylyx Pharmaceuticals's current Accumulated Depreciation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current Accumulated Depreciation of $0.00 Mil. The current Accumulated Depreciation is $0.00 Mil. Amylyx Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current Accumulated Depreciation is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amylyx Pharmaceuticals Business Description

Address 55 Cambridge Parkway, Suite 6W, Cambridge, MA, USA, 02142
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
33GF Score

Get the complete analysis for AMLX

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.15
Price